Pro-COPD
Conditions
Interventions
Treatment Group:Will receive Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Inhalation Aerosol, 2 inhalations twice daily. The investigator will provide inhalation technique ed
Control Group:Will not receive inhaled medication, only conventional antitussive drugs.
Sponsors
Beijing General Aerospace Hospital (formerly the 731 Hospital of China Aerospace Science and Industry Corporation
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 40 to 80 years old; Two of the three indicators, MMEF, FEF50%, and FEF75%, are less than 65%. 3. FEV1/FVC>=70%; 4. Those accompanied by one of the symptoms such as coughing, expectoration, or breathing difficulties; 5. No previous history of chronic obstructive pulmonary disease (COPD) or acute exacerbation of COPD; 6. There are no other imaging changes of lung diseases on CT scans, such as space-occupying lesions, exudations and interstitial changes. 7. No history of lung cancer, lobectomy or cystic fibrosis; 8. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have underlying lung diseases such as asthma, bronchiectasis and interstitial lung disease; 2. Have heart failure; 3. Are allergic to the study drug; 4. Do not wish to participate; 5. Pregnant; 6. Have other conditions that the researchers consider not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change value of pulmonary function (FEV1/FVC); | — |
Secondary
| Measure | Time frame |
|---|---|
| The change values of small airway function indicators (MMEF, FEF50%, FEF75%);The improvement of breathing difficulties symptoms; | — |
Countries
China
Contacts
Public ContactYan Peng
Beijing General Aerospace Hospital (formerly the 731 Hospital of China Aerospace Science and Industry Corporation
Outcome results
None listed